Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Vaccine. 2019 May 6;37(25):3267–3277. doi: 10.1016/j.vaccine.2019.04.075

Table 1.

Some evidence needed by the National Immunization Technical Advisory Group (NITAG) for the introduction of Immunization in Pregnancy vaccines.

  • Disease Burden

  • Epidemiology

  • Vaccine Safety

  • Efficacy

  • Effectiveness

  • Cost-effectiveness

  • Quality

  • Anticipated impact of the immunization program

  • Vaccines risk vs benefit for each target population

  • Feasibility and scheduling (how the vaccine would fit into the national immunization schedule)

  • Comparison of the impact of the vaccine with other interventions

  • Demand forecast for the vaccine

  • Regular and timely vaccine supply to meet the demand forecast

  • Disease’s visibility in society and how it compares to other public health concerns

  • Implementation costs of the new vaccine for pregnant women

  • Current immunization program’s performance (to identify areas that need to be strengthened)

  • Adequate infrastructure needed to monitor the disease burden and vaccine safety (maternal, fetal and infant adverse events)

  • Regulatory and ethical considerations